Dacheng Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dacheng Fan has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Haian Fu
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA
6 shared publications Yuhong Du
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, USA
5 shared publications- Andrey A. Ivanov
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, USA
3 shared publications - Danielle Cicka
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA
3 shared publications Qiankun Niu
3 shared publicationsAlafate Wahafu
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, USA
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by Elsevier in ASPET Discovery
- Vol. 2
Neo-protein-protein interaction rewires oncogenic BRAF mutations to the p53 tumor-suppressor machinery
- 9 June 2026
- Published by Elsevier in ASPET Discovery
- Vol. 2
Open AccessNeo-protein-protein interaction rewires oncogenic BRAF mutations to the p53 tumor-suppressor machinery
- Open Access
- 8 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer
Harnessing the power of immune system to treat cancer has become a core clinical approach. However, rewiring of intrinsic circuitry by genomic alterations enables tumor cells to escape immune surveillance, leading to therapeutic failure. Uncovering the molecular basis of how tumor mutations induce therapeutic resistance may guide the development of intervention approaches to advance precision immunotherapy. Here we report the identification of the Liver Kinase B1 (LKB1)-Inhibitor of Apoptosis Protein (IAP)- Janus Kinase 1 (JAK1) dynamic complex as a molecular determinant for immune response of LKB1-mut lung cancer cells. LKB1 alteration exposes a critical dependency of lung cancer cells on IAP for their immune resistance. Indeed, pharmacological inhibition of IAP re-establishes JAK1-regulated Stimulator of interferon genes (STING) expression and DNA sensing signaling, enhances cytotoxic immune cell infiltration, and augmentes immune-dependent anti-tumor activity in an LKB1-mutant immune-competent mouse model. Thus, IAP-JAK1-targeted strategies, like IAP inhibitors, may offer a promising therapeutic approach to restore the responsiveness of immunologically-cold LKB1-mutant tumors to immune checkpoint inhibitors or STING-directed therapies.
- 8 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessUncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer
Harnessing the power of immune system to treat cancer has become a core clinical approach. However, rewiring of intrinsic circuitry by genomic alterations enables tumor cells to escape immune surveillance, leading to therapeutic failure. Uncovering the molecular basis of how tumor mutations induce therapeutic resistance may guide the development of intervention approaches to advance precision immunotherapy. Here we report the identification of the Liver Kinase B1 (LKB1)-Inhibitor of Apoptosis Protein (IAP)- Janus Kinase 1 (JAK1) dynamic complex as a molecular determinant for immune response of LKB1-mut lung cancer cells. LKB1 alteration exposes a critical dependency of lung cancer cells on IAP for their immune resistance. Indeed, pharmacological inhibition of IAP re-establishes JAK1-regulated Stimulator of interferon genes (STING) expression and DNA sensing signaling, enhances cytotoxic immune cell infiltration, and augmentes immune-dependent anti-tumor activity in an LKB1-mutant immune-competent mouse model. Thus, IAP-JAK1-targeted strategies, like IAP inhibitors, may offer a promising therapeutic approach to restore the responsiveness of immunologically-cold LKB1-mutant tumors to immune checkpoint inhibitors or STING-directed therapies.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 93
Identification of Inhibitors of the TMPRss2 and SPIKE Interaction Through Novel uHTS Assays and Molecular Docking
ID 53428 Poster Board 93 The few therapies available for SARS-CoV-2 have limited areas of effectiveness and resistance is inevitable. Identification of inhibitors of viral entry has been challenging and have focused on the strong interaction between ACE2 and SPIKE. However, the interaction between TMPRss2 and SPIKE is also critical for viral entry and identification of inhibitors of this interaction could be therapeutic starting points. Therefore, we seek to develop ultra high-throughput assays for identification of inhibitors of the TMPRss2 and SPIKE interaction and prioritize top-hit compounds based on biophysical and molecular docking. We first created a Time Resolved-Forster/Fluorescence Energy Transfer (TR-FRET) assay utilizing fluorescently labeled antibodies to detect interactions between overexpressed SPIKE and TMPRss2 proteins in cell lysates. To further narrow the hits from this TR-FRET screen, we developed an orthogonal uHTS Nanoluciferase Binary Technology (NanoBiT) assay to detect the interaction between tagged SPIKE and TMPRss2 in live cells. With these orthogonal assays, we expanded our TR-FRET screen to over 100,000 compounds. Several compounds were found to show activity in both the TR-FRET and the NanoBiT assay. Thermal shift assays further narrowed down compounds by identifying compounds that bound to either SPIKE or TMPRss2 purified recombinant proteins, prioritizing potential compounds of interest. Next, molecular docking was done to identify which of the top compounds may directly disrupt the SPIKE/TMPRss2 interaction. MM-GBSA binding energies were calculated to determine potential ligand binding sites for each compound on the interface of TMPRss2 and SPIKE. Binding energies were also calculated for compound binding to allosteric sites on SPIKE or TMPRss2, based on which protein they interacted with in thermal shift data. SiteScores were also calculated for each binding site of the compounds to identify at which binding site they were most likely to interact with the protein of interest. A detailed evaluation of the binding energies at each site revealed the contributions of various types of bonds contributing to the binding energy of the compounds at each binding site and the residues important for the ligand and protein interaction. This revealed a potential mechanism of action for these candidate TMPRss2/SPIKE interaction disruptors. For example, eltrombopag was found to have favorable energy for being an allosteric modulator of the interaction, but also may act as direct disruptor of the interaction. Thus, we have identified several potential inhibitors of the SPIKE/TMPRss2 interaction through the use of our newly developed orthogonal TR-FRET and NanoBiT uHTS assays and characterized the binding sites via molecular docking. These uHTS assays may be a tool for future TMPRss2/SPIKE disruptor discovery and the identified candidate compounds could provide promising groundwork for further development of inhibitors of SARS-CoV-2. This research was supported in part by The Emory School of Medicine COVID Catalyst-I3 award, the NCI Emory Lung Cancer SPORE (HF, P50CA217691) Career Enhancement Program (AAI, P50CA217691), Emory initiative on Biological Discovery through Chemical Innovation (AAI).
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 93
Open AccessIdentification of Inhibitors of the TMPRss2 and SPIKE Interaction Through Novel uHTS Assays and Molecular Docking
ID 53428 Poster Board 93 The few therapies available for SARS-CoV-2 have limited areas of effectiveness and resistance is inevitable. Identification of inhibitors of viral entry has been challenging and have focused on the strong interaction between ACE2 and SPIKE. However, the interaction between TMPRss2 and SPIKE is also critical for viral entry and identification of inhibitors of this interaction could be therapeutic starting points. Therefore, we seek to develop ultra high-throughput assays for identification of inhibitors of the TMPRss2 and SPIKE interaction and prioritize top-hit compounds based on biophysical and molecular docking. We first created a Time Resolved-Forster/Fluorescence Energy Transfer (TR-FRET) assay utilizing fluorescently labeled antibodies to detect interactions between overexpressed SPIKE and TMPRss2 proteins in cell lysates. To further narrow the hits from this TR-FRET screen, we developed an orthogonal uHTS Nanoluciferase Binary Technology (NanoBiT) assay to detect the interaction between tagged SPIKE and TMPRss2 in live cells. With these orthogonal assays, we expanded our TR-FRET screen to over 100,000 compounds. Several compounds were found to show activity in both the TR-FRET and the NanoBiT assay. Thermal shift assays further narrowed down compounds by identifying compounds that bound to either SPIKE or TMPRss2 purified recombinant proteins, prioritizing potential compounds of interest. Next, molecular docking was done to identify which of the top compounds may directly disrupt the SPIKE/TMPRss2 interaction. MM-GBSA binding energies were calculated to determine potential ligand binding sites for each compound on the interface of TMPRss2 and SPIKE. Binding energies were also calculated for compound binding to allosteric sites on SPIKE or TMPRss2, based on which protein they interacted with in thermal shift data. SiteScores were also calculated for each binding site of the compounds to identify at which binding site they were most likely to interact with the protein of interest. A detailed evaluation of the binding energies at each site revealed the contributions of various types of bonds contributing to the binding energy of the compounds at each binding site and the residues important for the ligand and protein interaction. This revealed a potential mechanism of action for these candidate TMPRss2/SPIKE interaction disruptors. For example, eltrombopag was found to have favorable energy for being an allosteric modulator of the interaction, but also may act as direct disruptor of the interaction. Thus, we have identified several potential inhibitors of the SPIKE/TMPRss2 interaction through the use of our newly developed orthogonal TR-FRET and NanoBiT uHTS assays and characterized the binding sites via molecular docking. These uHTS assays may be a tool for future TMPRss2/SPIKE disruptor discovery and the identified candidate compounds could provide promising groundwork for further development of inhibitors of SARS-CoV-2. This research was supported in part by The Emory School of Medicine COVID Catalyst-I3 award, the NCI Emory Lung Cancer SPORE (HF, P50CA217691) Career Enhancement Program (AAI, P50CA217691), Emory initiative on Biological Discovery through Chemical Innovation (AAI).
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S152
Abstract 2582: Ultra High-Throughput Screening Assays for Inhibitors of TMPRSS2 and SPIKE Interaction
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S152
Open AccessAbstract 2582: Ultra High-Throughput Screening Assays for Inhibitors of TMPRSS2 and SPIKE Interaction
- Open Access
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 45, 116324
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer
- 1 September 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 45, 116324
Open AccessDiscovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer